Blog

Jan 20, 2019

China pharma must swallow that jagged little pill called R&D as government slashes profit margins of generic drugs

Posted by in categories: biotech/medical, government, policy

As Beijing’s pilot reform spreads nationwide to cut prices of drugs and improve their efficacy and safety, companies are under mounting pressure to invest in innovative drugs development and reduce reliance on low profit products that are the same copies of original drugs.


New policy environment demanding cheaper drugs adds pressure to innovate.

Read more

Comments are closed.